{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-23-000282","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.730765+00:00","generated_at":"2026-06-09T01:16:51.702519+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly Q3 revenue up 37% to $9.5B; reported EPS loss $0.06 on $3.29 IPR&D charges, non-GAAP EPS $0.10","bullets":["Revenue $9,498.6M (+37% YoY) driven by Mounjaro, Verzenio, and $1.42B from olanzapine rights sale.","Reported net loss of $57.4M ($0.06 loss per share); non-GAAP net income $94.8M ($0.10 EPS).","Acquired IPR&D charges of $3.29/share and olanzapine gain of $1.22/share impacted EPS.","2023 reported EPS guidance lowered to $5.95-$6.15; non-GAAP EPS to $6.50-$6.70.","Completed acquisitions of DICE, Versanis, Emergence, Sigilon; agreed to buy POINT Biopharma."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-23-000282","json":"https://secwatch.observer/filing/0000059478-23-000282.json","markdown":"https://secwatch.observer/filing/0000059478-23-000282.md","text":"https://secwatch.observer/filing/0000059478-23-000282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000282/0000059478-23-000282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000282/lly-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:16:51.702519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43c013c595228ddf66a4121381ca7ad381fab772","claim":"ELI LILLY & Co reported the third quarter of 2023 results: revenue $9,498.6, net income $(57.4), EPS $(0.06).","evidence_excerpt":"Revenue $9,498.6 $6,941.6 37% Net income (loss) – Reported (57.4) 1,451.7 NM Earnings (loss) per share – Reported (0.06) 1.61 NM","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000282/0000059478-23-000282-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"$9,498.6"},{"label":"Net income","value":"$(57.4)"},{"label":"EPS","value":"$(0.06)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}